N/A N=7 R5 Integrase Study in HIV-1 Naive Patients
HIV Infections
Primary: Viral Load — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=7 A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart
Diabetes Mellitus, Type 2
Primary: Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021) — -14.72; -15.35; -5.43; -9.12 milliseconds
Phase 3 N=493 Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients
Obesity
Primary: Percentage of Subjects Who Lose at Least 5 Percent of Baseline Body Weight After 24 Weeks of Treatment Weeks of Treatment — 49; 48; 33; 21 percentage of participants…
N/A N=594 Reduction in IV Associated Contamination
Post-operative Infections
Primary: Presence of Bacterial IV Stopcock Lumen Contamination — 41; 32 percent stopcock contamination rate
Phase 3 N=422 A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
Atopic Dermatitis
Primary: Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) — 21.67; 6.84; 3.84; 0.06…
N/A N=15 A New Approach for Controlling Hemostasis During Canal Treatment: a Pilot Study
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding Score — 2.33; 0.13 score on a scale — p=<.0001
Phase 3 N=32 Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Infections, Papillomavirus
Primary: Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 12 — 2 Participants
Phase 3 N=498 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
Melanoma
Primary: Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) — NA; 36.9; 23.1; 15.4…
Phase 2 N=1 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
Prostate Cancer
Primary: Overall Survival
Phase 2 N=99 A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging
Atherosclerosis
Primary: Change From Baseline of Mean of Maximum Tissue to Background Ratio (TBR) in the Qualifying Artery, Following 12 Weeks of Treatment in the Setting of Chronic Statin…
Phase 4 N=11 Pilot Study of Velcade® in IgA Nephropathy
Chronic Kidney Disease · IgA Nephropathy
Primary: Proteinuria — 2.52; 1.43 grams per 24 hrs
Phase 2 N=19 Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection
HIV Infections
Primary: Number of Participants With Serious Adverse Event — 0; 0 Participants
Phase 1 N=99 AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
Advanced Metastatic Breast Cancer
Primary: Adverse Events — 6; 13; 14; 10 Participants
N/A N=18 Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant
Liver Failure
Primary: Change in Creatinine Levels — 0.5; 0.55 MG/DL
N/A N=394 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 96.8; 100.0; 96.6; 95.0 percentage of participants